NextCell Pharma is an innovative Biotech growing out of the need for Advanced Therapy Medicinal Products for Autoimmune Disease and Transplantation. Cellaviva, the first Swedish family saving stem cell bank, with its expertise in umbilical cord stem cells and Diamyd Medical with its interests and investments within autoimmune diseases made a natural partnership for creating NextCell Pharma. Clinical trials testing NextCell Pharma’s first product, ProTrans,has started in Novermber 2018.
#nextcellpharma #cellaviva
Thank you to all the applicants for our Production Engineer and Head of Development positions! So many people wanting to join our team 😊
We have been inundated with applications and are slowing working through everyone's CVs. We thank you for your patience and will be in touch ASAP!
Nothing more uplifting, than hosting a full house of professionals sharing their results from Tience treatments and our excitement over the one of a kind innovation.
A few great moments from our Tience® Press and Customer Events last week ✨
We had an unforgettable day with over 100 guests eager to learn about the story of Tience. We also had the pleasure of hearing a very interesting talk by Hilkka Peltoniemi, MD, PhD, specialist in surgery and plastic surgery, on the regenerative power of human fat tissue. Linio Biotech's founder Riina Uusmies, PhD and cell biologist, went deeper into the science behind Tience and how it functions in the skin 🔬 It was a day filled with excellent questions, great conversations, and lots of excitement towards the remarkable potential of tissue science.
A big thank you to everyone who joined us and helped make the day as wonderful as it was!
#tience#skinreborn#regenerativeaesthetics
Congratulations to NextCell Pharma AB who this week, not only celebrate their 10 year anniversary in Advanced Therapy but have also announced the launch of their new advanced therapies analytics company, QVance.
https://lnkd.in/gib5Gjbq
🎉 NextCell Pharma: A Decade of Innovation and Growth! 🎉
This week marks a significant milestone for NextCell Pharma as we proudly celebrate our 10th #anniversary! From our beginnings as Cellaviva, a stem cell bank focused on preserving precious umbilical cord blood and tissue for families, we've embarked on an incredible journey of evolution and expansion to become the Nordic's largest private stem cell bank.
Today, NextCell Pharma AB stands at the forefront of advanced therapies, with a primary focus on our groundbreaking drug development program. Our proprietary umbilical cord mesenchymal cell therapy, #ProTrans, represents a novel approach in the treatment of autoimmune and inflammatory disorders. Through five clinical trials, ProTrans has demonstrated its potential to slowing disease progression, particularly in newly diagnosed #type1diabetes patients.
Our collaboration with several esteemed institutions has yielded promising results, as evidenced by our Phase II efficacy study published in Diabetologia 👉 https://lnkd.in/d2DvexSb. The study showcased ProTrans's ability to preserve #insulin production and reduce the need for supplementary insulin—an achievement that could revolutionize #diabetes treatment. Additionally, our commitment to innovation extends beyond diabetes, with ongoing trials exploring ProTrans' potential in treating viral-induced #pneumonia and severe pneumonia associated with #COVID-19 infection.
Our industrial mindset has enabled us to develop a scalable and patient-centric treatment approach, ensuring accessibility and convenience for patients. As we celebrate this milestone, we're thrilled to announce the launch of #QVance, a subsidiary dedicated to #quality control analytics. QVance underscores our commitment to #excellence and addresses the need for quality service providers in the #ATMPs field.
Over the past decade, the dedication of our remarkable #team fueled our journey in pursuit of scientific excellence. As we continue to expand our international presence, we remain steadfast in our vision of advancing innovative therapies that transform #healthcare.
#Sweden#Nordics#ATMP#10YearsAnniversary#Quality#MSC#StemCells#Biotech#CGT#CellandGeneTherapy#QCAnalysis#Biotechindustry#Development#Spinoff#Biologics#Pharmaceuticals#Scandinavia#LifeScience#Innovation#MarketGap#ClinicalTrials#Diabetologia#therapeutics#celltherapy#celltherapymanufacturing
